Jeffrey Javidfar1, Paul J Speicher1, Matthew G Hartwig1, Thomas A D'Amico1, Mark F Berry2. 1. Division of Thoracic Surgery, Department of Surgery, Duke University Medical Center, Durham, North Carolina. 2. Department of Cardiothoracic Surgery, Stanford University Medical Center, Stanford, California. Electronic address: berry037@stanford.edu.
Abstract
BACKGROUND: Multimodality treatment that includes esophagogastrectomy may represent the best option for curing accurately staged patients with esophageal cancer. We analyzed the impact of incomplete resection on outcomes after esophagogastrectomy for esophageal cancer. METHODS: The incidence of positive margins for patients who underwent esophagogastrectomy without induction therapy for pathologic T1-3N0-1M0 esophageal cancer of the mid and lower esophagus from 2003 to 2006 in the National Cancer Database was analyzed with multivariate logistic regression. The impact of positive margins on survival was assessed using Kaplan-Meier and Cox proportional hazards analysis. RESULTS: Positive margins occurred in 342 of 3,125 patients (10.9%) who met study criteria. Increasing clinical T status was an independent predictor of positive margins in multivariate analysis, but the chance of positive margins decreased with larger facility case volumes. The presence of clinical nodal disease was not predictive of an incomplete resection. The 5-year survival of patients with positive margins (13.8%, 95% confidence interval [CI]: 10.5% to 18.1%) was significantly worse than that for patients with negative margins (46.3%, 95% CI: 44.4% to 48.3%, p < 0.001). Both microscopic residual disease (hazard ratio 1.37, 95% CI: 1.16 to 1.60, p < 0.001) and gross residual disease (hazard ratio 1.98, 95% CI: 1.62 to 2.42, p < 0.001) predicted worse survival in multivariate analysis of the entire cohort. Receiving adjuvant chemoradiation therapy slightly improved 5-year survival of patients with positive margins (16.9%, 95% CI: 11.3% to 23.6%, versus 13.5%, 95% CI: 9% to 20.3%, p < 0.001). CONCLUSIONS: Positive margins are associated with poor survival, and adjuvant therapy only marginally improved prognosis. Future studies are needed to better evaluate whether induction therapy can lower the incidence of positive margins.
BACKGROUND: Multimodality treatment that includes esophagogastrectomy may represent the best option for curing accurately staged patients with esophageal cancer. We analyzed the impact of incomplete resection on outcomes after esophagogastrectomy for esophageal cancer. METHODS: The incidence of positive margins for patients who underwent esophagogastrectomy without induction therapy for pathologic T1-3N0-1M0 esophageal cancer of the mid and lower esophagus from 2003 to 2006 in the National Cancer Database was analyzed with multivariate logistic regression. The impact of positive margins on survival was assessed using Kaplan-Meier and Cox proportional hazards analysis. RESULTS: Positive margins occurred in 342 of 3,125 patients (10.9%) who met study criteria. Increasing clinical T status was an independent predictor of positive margins in multivariate analysis, but the chance of positive margins decreased with larger facility case volumes. The presence of clinical nodal disease was not predictive of an incomplete resection. The 5-year survival of patients with positive margins (13.8%, 95% confidence interval [CI]: 10.5% to 18.1%) was significantly worse than that for patients with negative margins (46.3%, 95% CI: 44.4% to 48.3%, p < 0.001). Both microscopic residual disease (hazard ratio 1.37, 95% CI: 1.16 to 1.60, p < 0.001) and gross residual disease (hazard ratio 1.98, 95% CI: 1.62 to 2.42, p < 0.001) predicted worse survival in multivariate analysis of the entire cohort. Receiving adjuvant chemoradiation therapy slightly improved 5-year survival of patients with positive margins (16.9%, 95% CI: 11.3% to 23.6%, versus 13.5%, 95% CI: 9% to 20.3%, p < 0.001). CONCLUSIONS: Positive margins are associated with poor survival, and adjuvant therapy only marginally improved prognosis. Future studies are needed to better evaluate whether induction therapy can lower the incidence of positive margins.
Authors: John D Birkmeyer; Andrea E Siewers; Emily V A Finlayson; Therese A Stukel; F Lee Lucas; Ida Batista; H Gilbert Welch; David E Wennberg Journal: N Engl J Med Date: 2002-04-11 Impact factor: 91.245
Authors: Justin B Dimick; Reid M Wainess; Gilbert R Upchurch; Mark D Iannettoni; Mark B Orringer Journal: Ann Thorac Surg Date: 2005-01 Impact factor: 4.330
Authors: J F Bosset; M Gignoux; J P Triboulet; E Tiret; G Mantion; D Elias; P Lozach; J C Ollier; J J Pavy; M Mercier; T Sahmoud Journal: N Engl J Med Date: 1997-07-17 Impact factor: 91.245
Authors: Mark F Berry; B Zane Atkins; Betty C Tong; David H Harpole; Thomas A D'Amico; Mark W Onaitis Journal: J Thorac Cardiovasc Surg Date: 2010-09-29 Impact factor: 5.209
Authors: Julian A Abrams; Donna L Buono; Joshua Strauss; Russell B McBride; Dawn L Hershman; Alfred I Neugut Journal: Cancer Date: 2009-11-01 Impact factor: 6.860
Authors: B Zane Atkins; Ashish S Shah; Kelley A Hutcheson; Jennifer H Mangum; Theodore N Pappas; David H Harpole; Thomas A D'Amico Journal: Ann Thorac Surg Date: 2004-10 Impact factor: 4.330
Authors: P J Speicher; X Wang; B R Englum; A M Ganapathi; B Yerokun; M G Hartwig; T A D'Amico; M F Berry Journal: Dis Esophagus Date: 2014-09-12 Impact factor: 3.429
Authors: David P Kelsen; Katryn A Winter; Leonard L Gunderson; Joanne Mortimer; Norman C Estes; Daniel G Haller; Jaffer A Ajani; Walter Kocha; Bruce D Minsky; Jack A Roth; Christopher G Willett Journal: J Clin Oncol Date: 2007-08-20 Impact factor: 44.544
Authors: Vignesh Raman; Oliver K Jawitz; Soraya L Voigt; Chi-Fu J Yang; Thomas A D'Amico; David H Harpole Journal: J Surg Res Date: 2020-01-08 Impact factor: 2.192
Authors: William M Whited; Jaimin R Trivedi; Emily R Bond; Victor H van Berkel; Matthew P Fox Journal: J Gastrointest Surg Date: 2017-09-22 Impact factor: 3.452
Authors: Ioannis Gkouzionis; Scarlet Nazarian; Michal Kawka; Ara Darzi; Nisha Patel; Christopher J Peters; Daniel S Elson Journal: J Biomed Opt Date: 2022-02 Impact factor: 3.758